{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:30:58Z","timestamp":1768534258192,"version":"3.49.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s41669-025-00608-9","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T09:51:02Z","timestamp":1765360262000},"page":"5-33","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1960-4552","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5937-0936","authenticated-orcid":false,"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-2612","authenticated-orcid":false,"given":"Hela","family":"Romdhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-2813","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-2463","authenticated-orcid":false,"given":"Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-8036","authenticated-orcid":false,"given":"Elamin","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-6467","authenticated-orcid":false,"given":"Salini","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Rowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-2315","authenticated-orcid":false,"given":"Matthew S.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"608_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Infect Dis. 2024;24(9):974\u20131002.","DOI":"10.1016\/S1473-3099(24)00176-2"},{"key":"608_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.rmed.2016.10.015","volume":"121","author":"M Kolditz","year":"2016","unstructured":"Kolditz M, Tesch F, Mocke L, H\u00f6ffken G, Ewig S, Schmitt J. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir Med. 2016;121:32\u20138.","journal-title":"Respir Med"},{"issue":"4","key":"608_CR3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.vaccine.2019.10.101","volume":"38","author":"JM McLaughlin","year":"2020","unstructured":"McLaughlin JM, Khan FL, Thoburn EA, Isturiz RE, Swerdlow DL. Rates of hospitalization for community-acquired pneumonia among US adults: a systematic review. Vaccine. 2020;38(4):741\u201351.","journal-title":"Vaccine"},{"key":"608_CR4","first-page":"1","volume":"167","author":"ZJ Peters","year":"2022","unstructured":"Peters ZJ, Ashman JJ, Schwartzman A, DeFrances CJ. National Hospital Care Survey Demonstration Projects: examination of inpatient hospitalization and risk of mortality among patients diagnosed with pneumonia. Natl Health Stat Rep. 2022;167:1\u20139.","journal-title":"Natl Health Stat Rep"},{"issue":"1","key":"608_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/03007995.2019.1675149","volume":"36","author":"V Divino","year":"2020","unstructured":"Divino V, Schranz J, Early M, Shah H, Jiang M, DeKoven M. The annual economic burden among patients hospitalized for community-acquired pneumonia (CAP): a retrospective US cohort study. Curr Med Res Opin. 2020;36(1):151\u201360.","journal-title":"Curr Med Res Opin"},{"issue":"14","key":"608_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2466-14-36","volume":"5","author":"H Ostermann","year":"2014","unstructured":"Ostermann H, Garau J, Medina J, Pascual E, McBride K, Blasi F. Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm Med. 2014;5(14):36.","journal-title":"BMC Pulm Med"},{"issue":"150","key":"608_CR7","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268822001182","volume":"8","author":"A Deb","year":"2022","unstructured":"Deb A, Podmore B, Barnett R, Beier D, Galetzka W, Qizilbash N, et al. Clinical and economic burden of pneumococcal disease among individuals aged 16 years and older in Germany. Epidemiol Infect. 2022;8(150):e204.","journal-title":"Epidemiol Infect"},{"issue":"2","key":"608_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11136-021-02941-y","volume":"31","author":"R O'Reilly","year":"2022","unstructured":"O\u2019Reilly R, Yokoyama S, Boyle J, Kwong JC, McGeer A, To T, et al. The impact of acute pneumococcal disease on health state utility values: a systematic review. Qual Life Res. 2022;31(2):375\u201388.","journal-title":"Qual Life Res"},{"key":"608_CR9","doi-asserted-by":"crossref","unstructured":"Schiess N, Groce NE, Dua T. The impact and burden of neurological sequelae following bacterial meningitis: a narrative review. Microorganisms. 2021;9(5):900.","DOI":"10.3390\/microorganisms9050900"},{"key":"608_CR10","unstructured":"WHO. Meningitis. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/meningitis. Accessed 7 Apr 2024"},{"issue":"1","key":"608_CR11","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/S2214-109X(16)30306-0","volume":"5","author":"T Shiri","year":"2017","unstructured":"Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51\u20139.","journal-title":"Lancet Glob Health"},{"issue":"3","key":"608_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.arbres.2022.12.015","volume":"59","author":"EM Dunne","year":"2023","unstructured":"Dunne EM, Cilloniz C, von Mollendorf C, Lewnard J, Grant LR, Slack MPE, et al. Pneumococcal vaccination in adults: what can we learn from observational studies that evaluated PCV13 and PPV23 effectiveness in the same population? Arch Bronconeumol. 2023;59(3):157\u201364.","journal-title":"Arch Bronconeumol"},{"key":"608_CR13","unstructured":"Food and Drug Administration. Label for 15-valent pneumococcal conjugate vaccine. https:\/\/nctr-crs.fda.gov\/fdalabel\/services\/spl\/set-ids\/1158fa93-ef41-4a29-8252-9251f94c53c8\/spl-doc?hl=Pneumococcal%2015-valent%20Conjugate%20Vaccine. Accessed 5 Oct 2024."},{"key":"608_CR14","unstructured":"Food and Drug Administration. Label for 20-valent pneumococcal conjugate vaccine. https:\/\/www.fda.gov\/media\/149987\/download. Accessed 5 Oct 2024."},{"key":"608_CR15","unstructured":"European Medicines Agency. Label for pneumococcal 15-valent conjugate vaccine. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxneuvance. Accessed 5 Oct 2024."},{"key":"608_CR16","unstructured":"European Medicines Agency. Label for pneumococcal 20-valent conjugate vaccine. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/prevenar-20-previously-apexxnar. Accessed 5 Oct 2024."},{"key":"608_CR17","unstructured":"Food and Drug Administration. Label for 21-valent pneumococcal conjugate vaccine. https:\/\/www.fda.gov\/media\/179426\/download?attachment. Accessed 5 Oct 2024."},{"key":"608_CR18","unstructured":"Centers for Disease Control and Prevention. Pneumococcal disease in adults and vaccines to prevent it. Last updated on September 12, 2024. https:\/\/www.cdc.gov\/pneumococcal\/prevent-pneumococcal-factsheet\/index.html. Accessed 3 Oct 2024."},{"issue":"3","key":"608_CR19","doi-asserted-by":"publisher","first-page":"2279394","DOI":"10.1080\/21645515.2023.2279394","volume":"19","author":"S Arya","year":"2023","unstructured":"Arya S, Norton N, Kaushik P, Brandtm\u00fcller A, Tsoumani E. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: a systematic review of published and grey literature. Hum Vaccin Immunother. 2023;19(3):2279394.","journal-title":"Hum Vaccin Immunother"},{"key":"608_CR20","unstructured":"European Center for Disease Prevenation and Control (ECDC). Vaccine scheduler. Pneumococcal disease: recommended vaccinations. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1. Accessed 3 Oct 2024."},{"issue":"36","key":"608_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","volume":"73","author":"M Kobayashi","year":"2024","unstructured":"Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, et al. Use of 21-valent pneumococcal conjugate vaccine among US adults: recommendations of the advisory committee on immunization practices\u2014United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(36):793\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"608_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11317060-000000000-00000","volume":"27","author":"DR Wright","year":"2009","unstructured":"Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics. 2009;27(9):713\u201323.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"608_CR23","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jval.2019.06.011","volume":"22","author":"T Shiri","year":"2019","unstructured":"Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329\u201344.","journal-title":"Value Health"},{"issue":"2","key":"608_CR24","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1093\/pubmed\/fdab159","volume":"44","author":"Z Tang","year":"2022","unstructured":"Tang Z, Matanock A, Jeon S, Leidner AJ. A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease. J Public Health (Oxf). 2022;44(2):e234\u201340.","journal-title":"J Public Health (Oxf)"},{"key":"608_CR25","doi-asserted-by":"crossref","unstructured":"Huang M, Xie J, Romdhani H, Song Y, Lee S, Liu D, et al. Global assessment of health utilities associated with pneumococcal disease in children-targeted literature reviews. Pharmacoeconomics. 2025;43(9):1001\u201345.","DOI":"10.1007\/s40273-025-01504-0"},{"issue":"5 Suppl 1","key":"608_CR26","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","volume":"14","author":"J Galante","year":"2011","unstructured":"Galante J, Augustovski F, Colantonio L, Bardach A, Caporale J, Marti SG, et al. Estimation and comparison of EQ-5D health states\u2019 utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health. 2011;14(5 Suppl 1):S60\u20134.","journal-title":"Value Health."},{"key":"608_CR27","doi-asserted-by":"crossref","unstructured":"Erickson P, Wilson R, Shannon I. Statistical notes no. 7: Years of healthy life. In: Healthy People 2000. Atlanta: Centers for Disease Control and Prevention, National Center for Health Statistics; 1995.","DOI":"10.1037\/e583992012-001"},{"key":"608_CR28","doi-asserted-by":"crossref","unstructured":"Torrance GW, Erickson P, Patrick DL, Feldman JJ. Technical notes. In: Erickson P, Wilson R, Shannon I. Statistical notes no. 7: Years of healthy life. Healthy People 2000. Atlanta: Centers for Disease Control and Prevention, National Center for Health Statistics; 1995.","DOI":"10.1037\/e583992012-001"},{"issue":"1","key":"608_CR29","first-page":"43","volume":"154","author":"JE Bennett","year":"2000","unstructured":"Bennett JE, Sumner W 2nd, Downs SM, Jaffe DM. Parents\u2019 utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med. 2000;154(1):43\u20138.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"608_CR30","doi-asserted-by":"crossref","unstructured":"Blommaert A, Hanquet G, Willem L, Theeten H, Thiry N, Bilcke J, et al. Use of pneumococcal vaccines in the elderly: an economic evaluation. Health Technology Assessment (HTA) Brussels : Belgian Health Care Knowledge Centre (KCE). 2016. KCE reports 274.","DOI":"10.57598\/R274C"},{"issue":"50","key":"608_CR31","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1016\/j.vaccine.2013.10.024","volume":"31","author":"BH Cho","year":"2013","unstructured":"Cho BH, Stoecker C, Link-Gelles R, Moore MR. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011\u201321.","journal-title":"Vaccine"},{"issue":"10","key":"608_CR32","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.4161\/hv.21571","volume":"8","author":"P Grzesiowski","year":"2012","unstructured":"Grzesiowski P, Aguiar-Ib\u00e1\u00f1ez R, Kobry\u0144 A, Durand L, Puig PE. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother. 2012;8(10):1382\u201394.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"608_CR33","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1080\/14760584.2023.2273892","volume":"22","author":"S Marbaix","year":"2023","unstructured":"Marbaix S, Mignon A, Taelman A, Averin A, Atwood M, Vietri J. Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Rev Vaccines. 2023;22(1):1008\u201321.","journal-title":"Expert Rev Vaccines"},{"issue":"7","key":"608_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199427","volume":"13","author":"S Marbaix","year":"2018","unstructured":"Marbaix S, Peetermans WE, Verhaegen J, Annemans L, Sato R, Mignon A, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65\u201384 years at elevated risk of pneumococcal infection. PLoS ONE. 2018;13(7):e0199427.","journal-title":"PLoS ONE"},{"issue":"5","key":"608_CR35","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1080\/21645515.2018.1428507","volume":"14","author":"L Willem","year":"2018","unstructured":"Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, et al. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vaccin Immunother. 2018;14(5):1218\u201329.","journal-title":"Hum Vaccin Immunother"},{"key":"608_CR36","unstructured":"Institute of Medicine Committee to Study Priorities for Vaccine D. The National Academies Collection: reports funded by National Institutes of Health. In: Stratton KR, Durch JS, Lawrence RS, editors. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington (DC): National Academies Press (US). Copyright 2000 by the National Academy of Sciences. All rights reserved.; 2000."},{"key":"608_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40814-019-0481-y","volume":"5","author":"MA Lloyd","year":"2019","unstructured":"Lloyd MA, Tang CY, Callander EJ, Janus ED, Karahalios A, Skinner EH, et al. Patient-reported outcome measurement in community-acquired pneumonia: feasibility of routine application in an elderly hospitalized population. Pilot Feasibility Stud. 2019;5:97.","journal-title":"Pilot Feasibility Stud"},{"key":"608_CR38","first-page":"00012","volume":"18;5(1)","author":"LN Clausen","year":"2019","unstructured":"Clausen LN, B\u00f8rgesen M, Ravn P, M\u00f8ller T. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study. ERJ Open Res. 2019;18;5(1):00012\u20132019.","journal-title":"ERJ Open Res"},{"issue":"1","key":"608_CR39","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","volume":"17","author":"MJ Mangen","year":"2017","unstructured":"Mangen MJ, Huijts SM, Bonten MJ, de Wit GA. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"608_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"MJ Mangen","year":"2015","unstructured":"Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407\u201316.","journal-title":"Eur Respir J"},{"issue":"9","key":"608_CR41","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2298\/VSP160905008Z","volume":"75","author":"N Zorni\u0107","year":"2018","unstructured":"Zorni\u0107 N, Milovanovi\u0107 D, Stojadinovi\u0107 M, Radovanovi\u0107 D, Davidovi\u0107 G, Simovi\u0107 S, et al. Quality of life of the mechanically ventilated patients with community-acquired pneumonia. Vojnosanit Pregl. 2018;75(9):864\u201374.","journal-title":"Vojnosanit Pregl"},{"issue":"14","key":"608_CR42","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/archinte.1996.00440130115012","volume":"156","author":"CM Coley","year":"1996","unstructured":"Coley CM, Li YH, Medsger AR, Marrie TJ, Fine MJ, Kapoor WN, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. Arch Intern Med. 1996;156(14):1565\u201371.","journal-title":"Arch Intern Med"},{"issue":"612","key":"608_CR43","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.3399\/bjgp13X669185","volume":"63","author":"R Oppong","year":"2013","unstructured":"Oppong R, Jit M, Smith RD, Butler CC, Melbye H, M\u00f6lstad S, et al. Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract. 2013;63(612):e465\u201371.","journal-title":"Br J Gen Pract"},{"issue":"2","key":"608_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10198-011-0360-9","volume":"14","author":"R Oppong","year":"2013","unstructured":"Oppong R, Kaambwa B, Nuttall J, Hood K, Smith RD, Coast J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough\/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14(2):197\u2013209.","journal-title":"Eur J Health Econ"},{"issue":"650","key":"608_CR45","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.3399\/bjgp16X686533","volume":"66","author":"R Oppong","year":"2016","unstructured":"Oppong R, Smith RD, Little P, Verheij T, Butler CC, Goossens H, et al. Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance. Br J Gen Pract. 2016;66(650):e633\u20139.","journal-title":"Br J Gen Pract"},{"issue":"16","key":"608_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12875-015-0282-1","volume":"27","author":"J Flamaing","year":"2015","unstructured":"Flamaing J, De Backer W, Van Laethem Y, Heijmans S, Mignon A. Pneumococcal lower respiratory tract infections in adults: an observational case-control study in primary care in Belgium. BMC Fam Pract. 2015;27(16):66.","journal-title":"BMC Fam Pract"},{"issue":"3","key":"608_CR47","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","volume":"4","author":"W Greiner","year":"2003","unstructured":"Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222\u201331.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"608_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"DG Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam health outcomes study: initial catalog of health-state quality factors. Med Decis Mak. 1993;13(2):89\u2013102.","journal-title":"Med Decis Mak"},{"issue":"2","key":"608_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/cid\/ciaa595","volume":"73","author":"HA Glick","year":"2021","unstructured":"Glick HA, Miyazaki T, Hirano K, Gonzalez E, Jodar L, Gessner BD, et al. One-year quality of life post-pneumonia diagnosis in Japanese adults. Clin Infect Dis. 2021;73(2):283\u201390.","journal-title":"Clin Infect Dis"},{"key":"608_CR50","unstructured":"Stouthard ME, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramers PG, Van de Water HP, Gunning-Schepers LJ, van der Maas PJ. Disability weights for diseases in the Netherlands. 1997. Available from: https:\/\/pure.uva.nl\/ws\/files\/3238153\/3276_ddw.pdf. Accessed 28 Apr 2024."},{"issue":"6","key":"608_CR51","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","volume":"36","author":"MR Gold","year":"1998","unstructured":"Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36(6):778\u201392.","journal-title":"Med Care"},{"issue":"2","key":"608_CR52","first-page":"3","volume":"23","author":"T Ikeda","year":"2017","unstructured":"Ikeda T, Yanagawa S, Murakami K, et al. Cost-utility analysis of a disability prevention program for community-dwelling older adults with mild disability in the urban area of Tokyo, Japan. Jpn J Human Sci Health Soc Serv. 2017;23(2):3\u201312.","journal-title":"Jpn J Human Sci Health Soc Serv."},{"issue":"11","key":"608_CR53","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1001\/archotol.125.11.1214","volume":"125","author":"AK Cheng","year":"1999","unstructured":"Cheng AK, Niparko JK. Cost-utility of the cochlear implant in adults: a meta-analysis. Arch Otolaryngol Head Neck Surg. 1999;125(11):1214\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5","key":"608_CR54","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/322587","volume":"33","author":"LJ Erickson","year":"2001","unstructured":"Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"608_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/01.AUD.0000134550.80305.04","volume":"25","author":"UK Cochlear Implant Study Group","year":"2004","unstructured":"UK Cochlear Implant Study Group. Criteria of candidacy for unilateral cochlear implantation in postlingually deafened adults II: cost-effectiveness analysis. Ear Hear. 2004;25(4):336\u201360.","journal-title":"Ear Hear"},{"issue":"3","key":"608_CR56","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1017\/S0266462300102132","volume":"16","author":"PF Krabbe","year":"2000","unstructured":"Krabbe PF, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care. 2000;16(3):864\u201373.","journal-title":"Int J Technol Assess Health Care"},{"key":"608_CR57","doi-asserted-by":"crossref","unstructured":"Lewis AT, Gergely V. Influence of Bone Conduction Hearing Implantation on Health-Related Quality of Life for Patients with Chronic Otitis Media. J Clin Med. 2022;11(18).","DOI":"10.3390\/jcm11185449"},{"issue":"8","key":"608_CR58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/MAO.0000000000003629","volume":"43","author":"BV Tailor","year":"2022","unstructured":"Tailor BV, Phillips JS, Nunney I, Yung MW. Comparison of disease-specific, generic, and hearing-specific instruments assessing health-related quality of life in patients undergoing middle ear surgery for chronic otitis media: a prospective correlational study. Otol Neurotol. 2022;43(8):931\u20136.","journal-title":"Otol Neurotol"},{"issue":"1","key":"608_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00405-022-07483-8","volume":"280","author":"AT Lewis","year":"2023","unstructured":"Lewis AT, Backous D, Choi BY, Jaramillo R, Kong K, Lenarz T, et al. Healthcare consumption among subjects with otitis media undergoing middle ear surgery-analysis of cost drivers. Eur Arch Otorhinolaryngol. 2023;280(1):175\u201381.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"608_CR60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1651-2227.2008.01136.x","volume":"98","author":"R Legood","year":"2009","unstructured":"Legood R, Coen PG, Knox K, Viner RM, El Bashir H, Christie D, et al. Health related quality of life in survivors of pneumococcal meningitis. Acta Paediatr. 2009;98(3):543\u20137.","journal-title":"Acta Paediatr"},{"issue":"12","key":"608_CR61","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, Trotter C, Glennie L, Hannigan L, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25(12):1529\u201344.","journal-title":"Health Econ"},{"key":"608_CR62","unstructured":"National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. NICE process and methods [PMG36]. Last updated on 31 October 2023.  https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed 14 May 2024."},{"key":"608_CR63","doi-asserted-by":"publisher","first-page":"1229524","DOI":"10.3389\/fpubh.2023.1229524","volume":"11","author":"G Gourzoulidis","year":"2023","unstructured":"Gourzoulidis G, Barmpouni M, Kossyvaki V, Vietri J, Tzanetakos C. Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Front Public Health. 2023;11:1229524.","journal-title":"Front Public Health"},{"issue":"1","key":"608_CR64","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1080\/13696998.2022.2152235","volume":"25","author":"J Olsen","year":"2022","unstructured":"Olsen J, Schnack H, Skovdal M, Vietri J, Mikkelsen MB, Poulsen PB. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23. J Med Econ. 2022;25(1):1240\u201354.","journal-title":"J Med Econ"},{"issue":"1","key":"608_CR65","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14760584.2023.2262575","volume":"22","author":"F K\u00fchne","year":"2023","unstructured":"K\u00fchne F, Achtert K, P\u00fcschner F, Urbanski-Rini D, Schiller J, Mahar E, et al. Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Rev Vaccines. 2023;22(1):921\u201332.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"608_CR66","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12962-023-00458-4","volume":"21","author":"BM Malene","year":"2023","unstructured":"Malene BM, Oyvind H, Tor M, David NM, Jens O, Nanna VK, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Eff Resour Alloc. 2023;21(1):52.","journal-title":"Cost Eff Resour Alloc."},{"issue":"8","key":"608_CR67","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","volume":"22","author":"D Mendes","year":"2022","unstructured":"Mendes D, Averin A, Atwood M, Sato R, Vyse A, Campling J, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22(8):1285\u201395.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"13","key":"608_CR68","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1016\/j.vaccine.2024.04.016","volume":"42","author":"K Owusu-Edusei","year":"2024","unstructured":"Owusu-Edusei K, Favre-Bulle A, Tsoumani E, Mutschler T, Cossrow N. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland. Vaccine. 2024;42(13):3239\u201346.","journal-title":"Vaccine"},{"key":"608_CR69","doi-asserted-by":"crossref","unstructured":"Restivo V, Baldo V, Sticchi L, Senese F, Prandi GM, Pronk L, et al. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness. Vaccines (Basel). 2023;11(7).","DOI":"10.3390\/vaccines11071253"},{"issue":"1","key":"608_CR70","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12955-018-0854-6","volume":"16","author":"LF Andrade","year":"2018","unstructured":"Andrade LF, Saba G, Ricard JD, Messika J, Gaillat J, Bonnin P, et al. Health related quality of life in patients with community-acquired pneumococcal pneumonia in France. Health Qual Life Outcomes. 2018;16(1):28.","journal-title":"Health Qual Life Outcomes"},{"key":"608_CR71","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2011.13228","volume":"141","author":"P Schuetz","year":"2011","unstructured":"Schuetz P, Albrich WC, Suter I, Hug BL, Christ-Crain M, Holler T, et al. Quality of care delivered by fee-for-service and DRG hospitals in Switzerland in patients with community-acquired pneumonia. Swiss Med Wkly. 2011;141:w13228.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"608_CR72","doi-asserted-by":"publisher","first-page":"78.e1","DOI":"10.1016\/j.cmi.2015.09.006","volume":"22","author":"M Dalager-Pedersen","year":"2016","unstructured":"Dalager-Pedersen M, Thomsen RW, Sch\u00f8nheyder HC, Nielsen H. Functional status and quality of life after community-acquired bacteraemia: a matched cohort study. Clin Microbiol Infect. 2016;22(1):78.e1-78.e8.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"608_CR73","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11908-016-0544-7","volume":"18","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Rubenfeld GD. Understanding long-term outcomes following sepsis: implications and challenges. Curr Infect Dis Rep. 2016;18(11):37.","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"608_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13104-019-4067-9","volume":"12","author":"C Gerlinger","year":"2019","unstructured":"Gerlinger C, Bamber L, Leverkus F, Schwenke C, Haberland C, Schmidt G, et al. Comparing the EQ-5D-5L utility index based on value sets of different countries: impact on the interpretation of clinical study results. BMC Res Notes. 2019;12(1):18.","journal-title":"BMC Res Notes"},{"key":"608_CR75","doi-asserted-by":"crossref","unstructured":"Roudijk B, Janssen B, Olsen JA. How Do EQ-5D-5L Value Sets Differ? In: Devlin N, Roudijk B, Ludwig K, editors. Value sets for EQ-5D-5L: a compendium, comparative review and user guide. Cham: Springer. Copyright 2022, The Author(s). 2022. p. 235-58.","DOI":"10.1007\/978-3-030-89289-0_6"},{"issue":"1","key":"608_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12874-022-01830-3","volume":"23","author":"A Sajjad","year":"2023","unstructured":"Sajjad A, Versteegh MM, Santi I, Busschbach J, Simon J, Roijen LH. In search of a \u201cpan-European value set\u201d; application for EQ-5D-3L. BMC Med Res Methodol. 2023;23(1):13.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"608_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1477-7525-3-17","volume":"21","author":"GM Lee","year":"2005","unstructured":"Lee GM, Salomon JA, LeBaron CW, Lieu TA. Health-state valuations for pertussis: methods for valuing short-term health states. Health Qual Life Outcomes. 2005;21(3):17.","journal-title":"Health Qual Life Outcomes"},{"key":"608_CR78","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"608_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1086\/313601","volume":"30","author":"P Vold Pepper","year":"2000","unstructured":"Vold Pepper P, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin Infect Dis. 2000;30(1):157\u201364.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"608_CR80","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1287\/opre.30.6.1043","volume":"30","author":"GW Torrance","year":"1982","unstructured":"Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res. 1982;30(6):1043\u201369.","journal-title":"Oper Res"},{"issue":"8","key":"608_CR81","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0895-4356(02)00448-1","volume":"55","author":"R Oostenbrink","year":"2002","unstructured":"Oostenbrink R, Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"7\u20138","key":"608_CR82","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.medmal.2009.02.019","volume":"39","author":"V des Portes","year":"2009","unstructured":"des Portes V. Long-term follow-up of bacterial meningitis\u2014sequels in children and adults: incidence, type, and assessment issues. Med Mal Infect. 2009;39(7\u20138):572\u201380.","journal-title":"Med Mal Infect"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00608-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00608-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:28:10Z","timestamp":1768472890000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00608-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00608-9","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MH, EE, and SM are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and may own stock and\/or hold stock options in Merck & Co., Inc. DR is a consultant for Merck & Co., Inc. and is a member of the EuroQol group. JX is an employee of XL Source, Inc., a consulting company that has provided paid consulting services to this research project. HR, YS, SL, and DL are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Merck & Co., Inc. MSK is a consultant for Merck & Co., Inc. and provided paid consulting services to this research project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"MH, EE, and SM contributed to the conceptualization of the study. All authors contributed to the study design and methodology. JX, HR, SL, and DL conducted the literature search and data extraction. MH and JX developed the initial summary of the results. All authors contributed to the interpretation of the findings, the development of the initial draft of the manuscript, and the revisions of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}